ORIGINAL RESEARCH article
Front. Pediatr.
Sec. Neonatology
Ceftazidime-avibactam for the treatment of multidrug-resistant or extensively drug-resistant bacteria infection in preterm infants: case series study and literature review
Provisionally accepted
- Department of Pediatrics, Peking University First Hospital, Beijing, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: To evaluate efficacy and safety of ceftazidime-avibactam (CZA) in preterm infants with multidrug-resistant (MDR) or extensive drug-resistant (XDR) bacterial infections. Method: Retrospective analysis of clinical data was conducted on data of preterm infants who were monitored in NICU of Peking University of First Hospital withfor MDR/XDR infections between 2022 and 2025. A literature search was performed using PUBMED and WANFANG databases., including demographic, clinical and microbiological characteristics, along with CZA treatment details. Results: Six preterm infants (median gestational age 26+3 weeks) received CZA treatment for MDR/XDR bacterial infections, including five bloodstream infections caused by carbapenem-resistant and extended-spectrum β-lactamase-producing Enterobacteriaceae and one ventilator associated pneumonia caused by carbapenem-resistant Pseudomonas aeruginosa. blaNDM-1 gene was detected in two patients via next-generation sequencing. CZA was used as monotherapy in three patients and as combination therapy with colistin or aztreonam in three patients. The median postnatal age at treatment initiation was 31 days. Five patients achieved clinical cure without adverse effects (AEs). One patient with concurrent CNS infection did not complete the treatment due to onset of unexpected status epilepticus. The literature search retrieved 44 preterm infants or neonates using CZA for sepsis or focal infections. Clinical cure rate was 84.09% (37/44). The most frequent AEs included liver function abnormalities, increased serum creatinine, hypomagnesemia and thrombocytopenia which were reversible. Conclusion: CZA alone or combined with aztreonam or colistin is effective and well-tolerated in critically ill preterm infants. However, the small sample size of patients limits the definitive conclusions about the safety profile of CZA, especially CNS risks. Further studies on the pharmacokinetics/pharmacodynamics and safety of CZA in preterm infants are warranted.
Keywords: Aztreonam, Ceftazidime-avibactam, drug-resistant bacteria infection, NGS, preterm infants
Received: 12 Oct 2025; Accepted: 28 Nov 2025.
Copyright: © 2025 Guang, Sang, Ru, Zhang, Feng, Wang and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Shan Li
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.